BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Two Melanoma Trials Fall as BMS and Nektar Report Disappointing Results

  Bristol Myers Squibb and Nektar Therapeutics said their joint Phase III PIVOT IO-001 study did not meet two endpoints: progression-free survival and objective response rate.

  March 14, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Ascendis, Can-Fite and BridgeBio Start the Week with Clinical Wins

  This week is starting off strong with some positive clinical news from Ascendis Pharma, Can-Fite and BridgeBio.

  March 14, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  New Data Reinforces Impact of Novartis’ Gene Therapy on SMA

  Novartis released new data Monday from its Phase III SPR1NT trial that reinforces the benefits of Zolgensma.

  March 14, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  Pfizer Halts Business in Russia, Suggests 4th Booster is Necessary

  Pfizer will cease operations within Russia and proceeds from its subsidiary in that country will be donated to provide direct humanitarian support to the people of Ukraine.

  March 14, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Career Advice

  Meet the Scientific Review Officer: Leaders of Peer Review

  Peer review is integral to the scientific process, and one group plays a bigger role than you might think: Scientific Review Officers.

  March 14, 2022

   · 

  5 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Tulane Nets $14 Million to Investigate Estrogen-Brain Link in Alzheimer’s

  An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.

  March 14, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Drug Development

  AstraZeneca Hits Roadblock in Nasal Polyps as FDA Wants More Data

  AstraZeneca’s Fasenra hit a roadblock after the FDA issued a Complete Response Letter for chronic rhinosinusitis with nasal polyps (CRSwNP).

  March 14, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  FDA

  COVID-19 Update: Impact of Asthma, Paxlovid Faces Production Issues

  A new study out of Duke University added weight to the determination that asthma in children did not increase infection risk, children slow to get COVID vaccine and more COVID-19 news.

  March 14, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  AstraZeneca’s Lynparza Bags Another Breast Cancer Indication

  The U.S. FDA has approved Lynparza for the adjuvant treatment of patients diagnosed with germline BRCA-mutated HER2-negative high-risk early breast cancer.

  March 14, 2022

   · 

  3 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  “Cornerstone” Sanofi Breast Cancer Drug Misses in Phase II

  Shares of Sanofi took a hit in premarket trading after it announced its Phase II breast cancer study assessing an experimental oral SERD failed to hit the mark.

  March 14, 2022

   · 

  2 min read

   · 

  Alex Keown